Bridgepoint Development Capital (BDC) has acquired Phlexglobal, a provider of Trial Master File and electronic Trial Master File solutions and services to the life sciences sector.
Phlexglobal was previously backed by Inflexion.
BDC will support Phlexglobal’s plans to develop technologies, expand its client base across pharma, biotech and contract research organisations and extend its global footprint.
Alan Payne, partner at BDC, says: “With the increasing emergence of technology in the TMF market, the company is now well placed to replicate its eminence in the services market to become the eTMF provider of choice and the leading TMF services brand.”
Stella Donoghue, Phlexglobal managing director, says: “We are very excited about working with BDC. They will bring a renewed energy and are focused on supporting our growth across the business. Our current management team will remain unchanged, continuing with the business to drive that growth.”
